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ABSTRACT 
 
Introduction: Inhaled & systemic steroids are one of the well-documented risks factors for 
Candida esophagitis. However, the role of gastric acid suppression remains controversial.  
Methods: We conducted a retrospective case-control study of 420 patients consisting of 84 cases 
of Candida esophagitis and 336 matched controls. Our cohort was gathered from subjects 
evaluated from 2001 to 2012. The diagnosis of Candida esophagitis was based on endoscopic 
and/or histological criteria.  
Results: On univariate analysis, proton pump inhibitors were associated with higher risk (OR = 
2.14; 95 % CI: 1.30 to 3.54); steroid use also increased the risk (OR = 3.55; 95% CI: 2.10 to 6.00). 
Furthermore, concurrent use of proton pump inhibitors & steroids substantially raised this risk (OR 
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= 13.8; 95% CI 5.07 to 37.5), suggesting a synergistic effect. When adjusted for covariates 
(cancer, chemotherapy/radiation, antibiotic use, hypothyroidism, anemia, chronic liver disease & 
diabetes), anemia decreased the odds ratio for proton pump inhibitors to 1.67 (95% CI 1.02 to 
2.75) and steroids to 1.69 (95% CI to 1.03 to 2.87). Hypothyroidism also substantially reduced the 
observed risk associated with steroid use. However, neither anemia nor hypothyroidism reduced 
the odds ratio for combined use of steroids and proton pump inhibitors. 
Conclusions: Our data suggests that patients who have been treated with steroids or proton 
pump inhibitors are at an increased risk for developing Candida esophagitis. Our data also 
suggests that steroids and proton pump inhibitors act synergistically to greatly increase the 
likelihood of Candida esophagitis. 
 
 
Keywords: Candida esophagitis; esophageal moniliasis; Candida albicans; proton pump inhibitor; 
gastric acid inhibitor. 
 
1. INTRODUCTION  
 
Esophageal candidiasis is known to occur in 
immuno-compromised patients, but has been 
less commonly reported in immuno-competent 
hosts. Esophageal candidiasis appears to occur 
when colonization of the esophagus is followed 
by subsequent invasion of the epithelial layer [1]. 
Colonization of the esophagus by Candida 
species is found in 20% of healthy adults [2-5].  A 
review by Ellepola et al. reported colonization 
with Candida species in 24-66% of patients using 
inhaled steroids [6]. It is one of the most common 
causes of infectious esophagitis [7-9]. Amongst 
Candida species, Candida albicans (C. albicans) 
is the most common & virulent causative 
organism, however, other species including C. 
tropicalis, C. krusei & C. stellatoidea have also 
been implicated [10].  
 
There are multiple physiologic defense 
mechanisms that normally inhibit colonization. 
Such mechanisms include salivation, mechanical 
clearance of esophageal luminal contents, a 
mucosal barrier, an intact pH gradient including 
gastric acidity, and normal bacterial and fungal 
flora. Proton pump inhibitors (PPIs) alter the 
gastric pH. In the study by Karmeli et al. [11] the 
gastric pH in patients treated with omeprazole 
was found to be greater than 4.5, which may 
predispose to floral migration and colonization of 
the stomach by oral bacteria and yeasts. 
Additionally, PPIs also decrease salivary 
secretion and subsequent clearance of 
esophageal luminal contents.  
 
Candida esophagitis (CE) has been associated 
with several risk factors, the most common being 
immunocompromised states such as acquired 
immunodeficiency syndrome (AIDS) [12-14]. 
Medical disorders such as diabetes mellitus, 
functional and mechanical esophageal 
obstruction, carcinomas, advanced age, 
alcoholism and use of certain medications, 
including corticosteroids, gastric acid 
suppressive therapies and antibiotics have also 
been linked to higher rates of CE [1-5,11,15-23] .  
 
In recent years, the use of PPIs has increased 
because of a number of contributing factors. 
Easy availability as an over the counter 
medication, generic formulation, low cost, 
increased incidence of dyspepsia, and 
gastroesophageal reflux disease (GERD), as well 
as the use of non-steroidal anti-inflammatory 
agents. PPIs are considered to be relatively safe 
and thus very commonly prescribed to treat 
conditions like gastritis, dyspepsia, GERD, 
duodenal ulcers, esophagitis and utilized in 
stress ulcer prophylaxis in hospitalized patients.  
 
Recent studies have suggested an association of 
PPIs with CE [1,11,15,23]. This class of drugs 
produces hypochlorhydria, which alters the 
physiologic gastric and esophageal environment 
and skews the balance of normal flora. This 
altered environment predisposes to commensal 
colonization by oral bacteria and yeast. 
Histamine Type-2 antagonists (H2 blockers), and 
prior vagotomy may have similar implications 
[21,24]. Oropharyngeal candidiasis is a well-
documented side effect of inhaled steroids [4-
6,22]. However limited data exists regarding the 
development of esophageal candidiasis in 
association with PPI use. The main aim of our 
study is to explore the association between the 
use of PPIs, corticosteroids and the risk of CE. 
 
2. MATERIALS AND METHODS  
 
2.1 Subjects  
 
We retrospectively identified 84 patients who 
were diagnosed with CE after undergoing upper 
endoscopy at our facilities between January 
2001 and January 2012.The diagnosis of CE was 
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made on the basis of endoscopy.  These patients 
were further matched with 336 patients who 
underwent upper endoscopy but had no CE 
(controls) based upon age and gender. We 
excluded all known Human immunodeficiency 
Virus (HIV) infected patients from our study.  
 
2.2 Protocol 
 
The study was conducted at two academic 
Medical Centers in the north eastern United 
States. The protocol was approved by the 
Institutional Review Board of the Saint Joseph’s 
Regional Medical Center in Paterson, New 
Jersey and Trinitas Regional Medical Center in 
Elizabeth New Jersey. The data gathered 
included patient demographics (age and sex), 
Human Immunodeficiency Virus (HIV) status, 
recent use of PPIs, H2 blockers, antibiotics, 
inhaled or systemic corticosteroids, history of 
diabetes mellitus, chronic liver disease, 
carcinoma, hypothyroidism, chemotherapy, 
radiation therapy, hypertension and anemia. 
 
2.3 Statistical Methods  
 
Descriptive statistics for interval data (age) were 
evaluated for fit-to normality by the D’Agostino-
Pearson omnibus normality test and found to not 
fit a normal distribution. Thus, age is expressed 
as median and interquartile range (IQR) and 
ages for cases and controls were compared by a 
nonparametric test (Mann-Whitney). Categorical 
data were described as counts and percents and 
were evaluated for group-wise differences by 
Fisher’s exact test for all univariate comparisons. 
As the study was conducted retrospectively, the 
effect size measurement used was the odds ratio 
(OR) and 95% CI. Multivariable analysis of 
exposures and outcomes were made using a 
binary logistic regression (BLR) mode, l which 
included as covariates any baseline 
characteristic deemed to be a potential 
confounder using p≤0.25 as the criterion for 
inclusion. This approach was used to estimate 
adjusted OR and 95% CI, as well as significant 
interaction between covariates and primary 
exposures. Rejection of the null hypothesis was 
based on a two-sided p-value ≤ 0.05 or exclusion 
of unity from the 95% 95% CI of the OR.  
Calculations were made using Prism® v. 5.04 
(GraphPad Corp. San Diego, CA) and SPSS v. 
21 (IBM Corp. Armonk, NY). 
 
3. RESULTS AND DISCUSSION 
 
3.1 Characteristics of Cases and Controls 
 
The baseline characteristics of cases and 
controls are given in Table 1. Few patients who 
were included in the study used H2 blockers, 
were recently post-operative or had evidence of 
rheumatologic disease. Thus, these 
characteristics could not be expected to 
demonstrate significant differences. Hypertensive 
subjects represented 55.9% of cases and 50.5% 
of controls; this difference was neither 
statistically significant nor within our criterion for 
inclusion in the BLR model. All other 
characteristics were, therefore, considered as 
potential confounders and included in the model. 
 
3.2 PPIs and Corticosteroids as Risk 
Factors  
 
The OR and 95% CI for the univariate analysis 
and adjusted OR are shown in Fig. 1. Upon 
performing univariate analysis, PPIs were 
associated with a higher risk of CE (OR = 2.14; 
95% CI: 1.30 to 3.54); steroid use also  
 
Table 1. Baseline characteristics of patients in our study 
 
Particulars Cases (n=84) Controls (n= 336) P value 
Age in years : Median (IQR) 67.5 (56.0 - 78.0) 67.0 (56.0-77.0) 0.817 
Gender: Male/Female 42/42 168/168 1.000 
Proton Pump Inhibitors 34 (40.5%) 81 (24.1%) 0.004 
H2 Blockers 2 (2.3%) 3 (0.89%) 0.574 
Cotricosteroid therapy 34 (40.5%) 54 (16.0%) 0.0001 
Diabetes Type 1 and 2 32 (38%) 100 (29.7%) 0.18 
Carcinoma 5 (5.9%) 44 (13.0%) 0.102 
Antibiotics 11 (13.1%) 27 (8.03%) 0.217 
Chronic liver disease 6 (7.14%) 115 (34.2%) 0.0001 
Hypertension 47 (55.9%) 170 (50.5%) 0.449 
Anemia 35 (41.6%) 101 (30.05%) 0.003 
Rheumatologic diseases 6 (7.14%) 9 (2.6%) 0.6343 
Surgery 2 (2.3%) 6 (1.7%) 0.929 
Chemotherapy/radiation 6 (7.14%) 19 (5.6%) 0.066 
Hypothyroidism 9 (10.7%) 20 (5.9%) 0.01 
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Fig. 1. Forest plots of OR and 95% CI for PPI use as primary exposure (Fig. 1A, top panel), 
steroid use as primary exposure (Fig. 1B, middle panel) and combined use of PPI and steroids 
vs. use of neither (Fig. 1C, bottom panel) 
Univariate OR is at bottom of each forest plot, indicated by the open diamond. Closed diamonds are used to 
indicate OR adjusted for each of the potential confounders 
 
increased the risk of CE (OR = 3.55; 95% CI: 
2.10 to 6.00). In the caes of PPIs, only anemia 
substantially decreased the risk of CE (adjusted 
OR: 1.67 [95% CI 1.02 to 2.75)]; nevertheless, 
this comorbidity did not eliminate, completely, the 
odds of developing CE in subjects being treated 
with PPI.  Similarly, anemia [adjusted OR: 1.69 
(95% CI to 1.03 to 2.87)] as well as 
hypothyroidism were covariates decreasing the 
risk of CE. In both cases, there was a substantial 
decrease in the OR but, as is the case of PPI, 
these co morbidities did not completely obviate 
the risk of CE. Furthermore, concurrent use of 
PPIs & steroids substantially raised this risk (OR 
= 13.8; 95% CI 5.07 to 37.5), suggesting a 
synergistic effect. When adjusted for covariates 
(cancer, chemotherapy/radiation, antibiotic use, 
hypothyroidism, anemia, chronic liver disease & 
diabetes), anemia was found to decrease the 
odds ratio for PPI to 1.67 (95% CI 1.02 to 2.75) 
and for steroids to 1.69 (95% CI to 1.03 to 2.87). 
Hypothyroidism also substantially reduced the 
observed risk associated with steroid use. 
However, neither anemia nor hypothyroidism 
reduced the odds ratio for combined use of 
steroids and PPI.  This OR was not affected to 
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any extent by the presence of cancer, diabetes, 
antibiotic use or chemotherapy or radiation 
therapy. There was a slight, but insignificant 
increase in the OR adjusted for anemia and a 
similarly insignificant decrease in the OR 
adjusted for hypothyroidism. Chronic liver 
disease increased the odds of CE by 38%; 
however, despite this apparently large effect on 
the OR for combined use of PPI and steroids, the 
interaction term was not statistically significant, 
most likely due to the extremely large confidence 
interval. 
 
In this retrospective case control study involving 
eighty-four non-HIV/AIDS patients with CE,      
we found that previously recognized risk    
factors like steroid therapy, diabetes (type I     
and II), carcinoma, chemotherapy/radiation, 
hypothyroidism, antibiotics and chronic liver 
disease did correlate with the development of 
esophageal candidiasis. However, the most 
prominent finding was the synergistic risk of PPIs 
and steroid use with the prevalence of CE.  
 
There is scant published evidence reporting the 
relationship between esophageal candidiasis and 
PPIs [1,11,15,23]. The relationship of inhaled 
and/or intravenous steroid and esophageal 
candidiasis is better documented in the literature 
[4,5,6,22]. Fidan et al. [4] reported a 42.9% 
frequency of esophageal candidiasis in a 21-
person cohort compared to a 0.2% rate in their 
control group. Kanda et al. [22] (n=49) reported a 
37% prevalence of esophageal candidiasis in 
patients using inhaled fluticasone propionate 
compared to 0.3% of controls. To our knowledge 
this is the only case control study so far, 
analyzing the association of PPIs and steroids 
use with CE. Our study has certain limitations. It 
is a retrospective study and it does not specify 
duration of exposure to PPIs. Finally, it does not 
stratify for active comorbidities, which may 
increase the risk of CE. Moreover, as is the case 
with any case-control study, controls with active 
exposure to risk factors preclude a true 
association with risk. The observation that 
anemia and hypothyroidism both have the effect 
of decreasing the adjusted OR for PPI and 
steroids.  One should consider the possibility that 
these are merely secondary effects of 
therapeutic approaches to these comorbidities 
rather than effects directly attributable to the 
specific comorbidity. We did not examine that 
prospect and suggest that a larger, prospective 
cohort study, stratifying covariates by 
duration/intensity as well as additional exposures 
attendant to these covariates, might provide 
additional insight into this issue. 
 
4. CONCLUSION 
 
Our data suggests that patients who have been 
treated with steroids or proton pump inhibitors 
are at an increased risk for developing Candida 
esophagitis. Our data also suggests that steroids 
and proton pump inhibitors act synergistically to 
greatly increase the likelihood of Candida 
esophagitis. So on the basis of this finding we 
recommend that PPIs be used judiciously, only in 
clinical conditions where they are indicated and 
have been proven efficacious. Also physicians 
should re-evaluate patients at each clinical 
encounter for the possibility of PPI and/or 
corticosteroid therapy discontinuation. 
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